| |
Newsroom /
Science and Research
/
Science and Research
/
Kidney and Renal Diseases Therapeutics Market to 2017
Kidney and Renal Diseases Therapeutics Market to 2017
The Kidney and Renal Diseases Therapeutics Market is Forecast to Show Moderate Growth Until 2017, it provides insights into the global kidney and renal diseases therapeutics market and market forecasts until 2017.
London,
London,
United Kingdom
(prbd.net)
15/06/2011
The Kidney and Renal Diseases Therapeutics Market is Forecast to Show Moderate Growth Until 2017, it provides insights into the global kidney and renal diseases therapeutics market and market forecasts until 2017.
GBI Research’s analysis suggests that the global kidney and renal diseases therapeutics market
was worth $50.3 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR)
of 5.5% for the next seven years, to reach $73 billion by 2017. The global market revenues are
expected to increase due to the introduction of new therapies which are currently in the regulatory
filing stage, and those in the later stages of development. These drugs include antioxidant
inflammatory modulators, metal-free phosphate binders with improved safety and efficacy,
nutritional supplements and iron replacement therapies.
GBI Research analyzed the current competitive landscape for kidney and renal disease drugs and
found the competition to be weak. There are more than 12 marketed products for the treatment of
CKD, including angiotensin II receptor blockers (ARB), Angiotensin Converting Enzyme (ACE)
inhibitors, phosphate binders, Erythropoietin (EPO) and iron replacement products. Although these
products are moderately effective in controlling the progression of CKD, the serious adverse effects
of these products have resulted in the discontinuation of therapies amongst patients. The market is
in need of a first-in-class product which is efficient in slowing down the progression of CKD.
For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Kidney-and-Renal-Diseases-Therapeutics-Market-to-2017-Strong-Pipeline-and-Unmet-Need-Due-to-Poor-Safety-Profiles-and-to-Create-Opportunities-for-Growth&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
GBI Research, the leading business intelligence provider, has released its latest research, “Kidney
and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to
Poor Safety Profiles to Create Opportunities for Growth”, which provides insights into the
global kidney and renal diseases therapeutics market and market forecasts until 2017. The report
provides an in-depth analysis of the top four therapeutic indications of kidney and renal diseases,
which includes chronic kidney disease, renal anemia, diabetic nephropathy and acute kidney injury.
The report also examines the global kidney and renal disease treatment usage patterns for the
covered indications. In addition, the report also includes insights into the kidney and renal diseases
R&D pipeline. GBI Research analysis shows that the overall global kidney and renal diseases
market for the four indications, chronic kidney disease, renal anemia, diabetic nephropathy and
acute kidney injury was valued at $50.3 billion in 2010. The market is expected to witness growth at
a CAGR of 5.5% for the forecast period, and will reach $73 billion by 2017. The global market
revenues are expected to increase due to the introduction of new therapies which are currently in
the regulatory filing stage, and those in the later stages of development. These drugs include
antioxidant inflammatory modulators, metal-free phosphate binders with improved safety and
efficacy, nutritional supplements and iron replacement therapies.
It is built using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by GBI Research’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Kidney-and-Renal-Diseases-Therapeutics-Market-to-2017-Strong-Pipeline-and-Unmet-Need-Due-to-Poor-Safety-Profiles-and-to-Create-Opportunities-for-Growth&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GBI Research is a global market intelligence services company providing information research and analysis products and services.
|